UNITED NATIONS

NATIONS UNIES

WORLD HEALTH ORGANIZATION

ORGANISATION MONDIALE DE LA SANTÉ

EXECUTIVE BOARD

Fourth Session

EB4/20
8 July 1949

ORIGINAL: ENGLISH

APPLICATION FOR WHO APPROVAL OF THE YELLOW FEVER VACCINE MANUFACTURED AT THE INSTITUT PASTEUR, PARIS

As a result of a decision taken by the Interim Commission at its Fourth Session (September 1947), all yellow fever vaccines, in respect of which WHO approval was to be sought, are required to be subjected to potency titration by two or more control laboratories, recognized for the purpose by WHO under Article 36 (11) of the International Sanitary Convention for Aerial Navigation, 1944.

Therefore, when application was received from the Director of the Institut Pasteur, Paris, that the yellow fever vaccine manufactured there be subjected to the necessary tests, he was requested on 13 July 1948 to forward, in containers provided by WHO, samples for potency titration to the three following laboratories: the Wellcome Laboratories of Tropical Medicine, London; the Laboratory of Biologics Control, National Institutes of Health, Bethesda; and the Laboratories of the International Health Division, Rockefeller Institute, New York.

Results of potency titration showed that the vaccine, in its recommended dosage, had a content much in excess of the 500 MLD laid down for the satisfactory immunization of man in the Standards for the Manufacture and Control of Yellow Fever Vaccine, but an excess which is recommended in those Standards.

All members of the Yellow Fever Panel concerned with the laboratory evaluation of yellow fever vaccines, viz., Médecin général C. Durieux, Dr. A.F. Mahaffy, Dr. R.M. Taylor and Dr. M.V. Veldee, to whom the results were communicated, consider the vaccine to be in every way suitable for international use and recommend its approval by WHO.

The Executive Board may therefore wish to adopt the following resolution:

The Executive Board:

APPROVES for international use, the yellow fever vaccine produced by the Institut Pasteur, Paris.